Otsuka Holdings Reports Strong FY2024 Financial Growth

Otsuka Holdings Co ( (OTSKF) ) has released its Q4 earnings. Here is a breakdown of the information Otsuka Holdings Co presented to its investors.

Otsuka Holdings Co is a diversified healthcare company operating primarily in the pharmaceutical and nutraceutical sectors, known for its innovative products and solutions addressing global health challenges. The company recently reported its financial results for FY2024, showcasing significant growth across its key business areas. Otsuka’s revenue increased by 15.4% year-over-year to ¥2,329.9 billion, driven by the strong performance of its pharmaceutical and nutraceutical businesses. This growth was particularly fueled by increased sales of high-margin products and strategic expansion in North America and Asia. Notably, the company’s net profit saw a substantial rise of 182.1%, reaching ¥343.1 billion, partly due to favorable tax adjustments in the United States. The pharmaceutical segment reported a 17.1% increase in revenue, supported by robust sales of key medications such as ABILIFY MAINTENA and JYNARQUE. Meanwhile, the nutraceutical business grew by 15.2%, with significant contributions from products targeting women’s health. Looking ahead, Otsuka plans to continue its momentum by leveraging its innovative capabilities and expanding its market presence. The company aims to achieve record-high revenue in FY2025, with ongoing investments in R&D and strategic growth initiatives, while carefully managing the impact of potential product exclusivity losses.